BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Civan J, Hann HW. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough? Expert Opin Drug Saf. 2015;14:865-875. [PMID: 25826452 DOI: 10.1517/14740338.2015.1032243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
2 Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016;10:407-414. [PMID: 26739135 DOI: 10.1007/s12072-015-9692-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
3 Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. Eur J Gastroenterol Hepatol 2017;29:56-60. [PMID: 27669175 DOI: 10.1097/MEG.0000000000000749] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Review of Hematology 2017;11:57-70. [DOI: 10.1080/17474086.2018.1407645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]